(SLXP)


NasdaqGS . Currency in USD
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
OpenN/A
Prev CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52wk Rangeundefined - undefined
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
BetaN/A
VolumeN/A
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Market Realistlast month

    Valeant: Are the Salix and Dermatology Portfolios Recovering?

    Salix is one of Valeant’s (VRX) core businesses. To gain growth momentum, the Salix and dermatology portfolios are crucial for Valeant.

  • American City Business Journals2 months ago

    Valeant gets new approval for legacy Salix drug

    Embattled drug giant Valeant Pharmaceuticals International (VRX) heard some much-needed good news when the U.S. Food and Drug Administration approved a drug that has deep roots in Raleigh. Specifically, FDA approved Relistor tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. The drug was a legacy product of Salix Pharmaceuticals, the Raleigh pharmaceutical company Valeant acquired in 2015.

  • TheStreet.com2 months ago

    Valeant's Drug Approvals May Save the Day

    Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.